Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.The Motley Fool • 07/29/26
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 EarningsZacks Investment Research • 07/28/26
There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam CompoundersInvestors Business Daily • 07/23/26
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?Zacks Investment Research • 07/23/26
Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 PoundsForbes • 07/23/26
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.The Motley Fool • 07/23/26
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trialsCNBC • 07/23/26
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1CPRNewsWire • 07/23/26
The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side24/7 Wall Street • 07/22/26